Use of an Antiemetic to Shorten the Length of Labor in Nulliparous Women

Sponsor
Ain Shams University (Other)
Overall Status
Completed
CT.gov ID
NCT01937234
Collaborator
Armed Forces Hospitals, Southern Region, Saudi Arabia (Other)
250
1
2
38
6.6

Study Details

Study Description

Brief Summary

Reducing the length of labor is a highly desirable goal of intrapartum care, both from a perspective of maternal and fetal well-being , and for the providers of the birth services. Avoiding a long , protracted labor entails shorter exposure to pain anxiety and stress and would translate into a major improvement in maternal satisfaction with the child birth experience.

The purpose of this study is to determine the effectiveness of metoclopramide for reducing the duration of spontaneous labor among nulliparous women managed according to a standard intrapartum protocol.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

Women who will fulfill the study inclusion and exclusion criteria and agree to be included in the study will be randomized assigned to receive either an intravenous injection of 10mg metoclopramide (Group 1) or the same volume of placebo, i.e. 0.9% sodium chloride (Group2). Randomization will be achieved using computer generated randomization sequences. Allocation will be in 1:1 ratio. Record of group allocation will be maintained by a resident physician whose responsibility is randomization and drawing up the injection, but has no direct involvement in the intrapartum decision making.

After through history and physical examination, each participant will take the selected medication slowly IV over 2 min, the assigned medication will be repeated every two hours for a maximum of three doses.

Monitoring of fetal well-being and labor progress with Partographic representation will be performed.

Management of labor will be according the labor and delivery standard protocol, if labor dilatation will not progress appropriately, i.e. cervical dilatation rate of <1cm/hour, amniotomy will be performed if membranes are intact. Oxytocin augmentation will be considered after rupture of membranes only if the cervix remains unchanged on two consecutive pelvic examination conducted two hours apart. Oxytocin infusion will start with 5mIU/min and increase by 5mIU/min every 15min to achieve seven contractions in 15 min, the maximal rate of oxytocin being 30Miu/min.

The following parameters will be recorded for every patient:
  • Timing of metoclopramide or placebo injections

  • Timing of full dilatation of cervix

  • Duration of first stage of labor

  • Duration of second stage of labor

  • Duration of third stage of labor

  • Mode of delivery

  • Injection to delivery interval

  • Cervical dilatation rate

  • Neonatal condition at birth

Study Design

Study Type:
Interventional
Actual Enrollment :
250 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Use of an Antiemetic to Shorten the Length of Labor in Nulliparous Women, Exploring a Potential Role of an Old Drug
Study Start Date :
Jul 1, 2013
Actual Primary Completion Date :
Jul 1, 2016
Actual Study Completion Date :
Sep 1, 2016

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Metoclopramide

Intravenous injection of 10mg metoclopramide

Drug: Metoclopramide
Intravenous injection of 10mg metoclopramide, at enrollment, then every 2 hours. Maximum of 3 doses.
Other Names:
  • Primperan (Trademark)
  • Placebo Comparator: Placebo

    Intravenous injection of 0.9% sodium chloride

    Drug: Placebo
    Intravenous injection of 0.9% sodium chloride, at enrollment, then every 2 hours. Maximum of 3 doses.
    Other Names:
  • Normal saline
  • Outcome Measures

    Primary Outcome Measures

    1. Cervical dilatation rate [6 hours]

    Secondary Outcome Measures

    1. Duration of the first stage of labor [6 hours]

    Other Outcome Measures

    1. Duration of the second stage of labor [2 hours]

    2. Duration of the third stage of labor [1 hour]

    3. Number of Participants with Adverse Events [24 hours]

      Adverse effects of metoclopramide: Cardiovascular: heart block, bradycardia, heart failure, flushing, hyper or hypotension, supraventricular tachycardia. Central nervous system: Drowsiness, acute dystonic reactions, headache, dizziness, akathisia, confusion, depression, hallucinations, Parkinsonian-like symptoms, suicidal ideation, seizure, tardive dyskinesia Dermatologic: Angioneurotic edema, rash, urticaria Gastrointestinal: Nausea, vomiting, diarrhea Respiratory: Bronchospasm, laryngeal edema (rare), laryngospasm (rare)

    4. Apgar score [10 minutes]

    5. Meconium stained liquor [6 hours]

    6. Neonatal intensive care unit admission rate [24 hours]

    7. Rate of vaginal delivery [12 hours]

    8. Number of participants with genital tract injuries [2 hours]

      genital tract injuries: Perineal tears Vaginal tears Cervical tears Perineal hematomas Vaginal hematomas Uterine rupture

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 35 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Primigravida

    • Singleton pregnancy

    • Term gestation i.e. 37- 42 weeks

    • Sure reliable dates

    • Vertex presentation, occipitoanterior position

    • Spontaneous onset of labor

    • Regular uterine contractions at every 5 min ,each lasting for 20 sec

    • Cervical dilatation of 3-5cm

    • With or without rupture of membranes

    • No evidence of maternal or fetal distress

    Exclusion Criteria:
    • Mal-presentations

    • Mal-positions

    • Multifetal pregnancy

    • Cephalopelvic disproportion

    • history of cervical surgery or injury

    • Hypersensitivity to metoclopramide

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Labor and delivery ward of Armed Forces Hospital, Southern Region. Khamis Mushait Saudi Arabia 101

    Sponsors and Collaborators

    • Ain Shams University
    • Armed Forces Hospitals, Southern Region, Saudi Arabia

    Investigators

    • Study Director: Mohamed I Ellaithy, MD, Ain Shams University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Mohamed Ellaithy, Lecturer of Obstetrics & Gynecology, Ain Shams University
    ClinicalTrials.gov Identifier:
    NCT01937234
    Other Study ID Numbers:
    • AFHSR-13-7-2013
    First Posted:
    Sep 9, 2013
    Last Update Posted:
    Mar 10, 2017
    Last Verified:
    Mar 1, 2017
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 10, 2017